Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Smoking and schizophrenia.

J B Lohr1, K Flynn

  • 1Department of Psychiatry, University of California, San Diego.

Schizophrenia Research
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Patients with schizophrenia exhibit a nearly 90% smoking prevalence, significantly higher than the general population. The complex reasons for this high rate in schizophrenia are still under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cold water swimming and its potential health benefits - a qualitative study of participants' views and experiences.

Irish medical journal·2023
Same author

Air Pollution Levels Outside the Capital's Maternity Hospitals.

Irish medical journal·2022
Same author

Equine herpesvirus-1 genotype did not significantly affect clinical signs and disease outcome in 65 horses diagnosed with equine herpesvirus-1 myeloencephalopathy.

Veterinary journal (London, England : 1997)·2020
Same author

Raman spectroscopic mapping for the analysis of solar radiation induced skin damage.

The Analyst·2013
Same author

Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study.

Current pharmacogenomics and personalized medicine·2011
Same author

Differences in SMN1 allele frequencies among ethnic groups within North America.

Journal of medical genetics·2009
Same journal

Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.

Schizophrenia research·2026
Same journal

Converting negative symptom dimension scores across SANS and PANSS.

Schizophrenia research·2026
Same journal

Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.

Schizophrenia research·2026
Same journal

One social interaction after another: Dynamic modeling of social experience in schizophrenia.

Schizophrenia research·2026
Same journal

Reduced synaptic plasticity and E/I imbalance drive peripersonal space boundaries expansion in schizophrenia.

Schizophrenia research·2026
Same journal

Complete blood count-derived inflammatory markers and symptom phenotypes in schizophrenia spectrum disorders: A hierarchical clustering analysis.

Schizophrenia research·2026
See all related articles

Area of Science:

  • Psychiatry
  • Neuroscience
  • Addiction Research

Background:

  • Schizophrenia patients demonstrate a markedly high smoking prevalence, nearing 90%.
  • This rate significantly exceeds that of the general population (33%) and individuals with other psychiatric conditions (45-70%).

Purpose of the Study:

  • To highlight the exceptionally high smoking rates in schizophrenia.
  • To underscore the unknown etiology behind this phenomenon.

Main Methods:

  • Literature review of existing studies on smoking prevalence in schizophrenia.
  • Comparative analysis of smoking rates across different populations.

Main Results:

  • Confirmed a smoking prevalence of approximately 90% in patients with schizophrenia.

Related Experiment Videos

  • Established a significant disparity in smoking rates compared to general and other psychiatric populations.

    • Conclusions:

    • The high prevalence of smoking in schizophrenia is a critical public health concern.
    • The underlying reasons are likely multifactorial, involving psychopathological, biochemical, and neuropharmacological interactions specific to schizophrenia and smoking behavior.